<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33867475</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1524-4725</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>47</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Aug</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]</Title>
          <ISOAbbreviation>Dermatol Surg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RZL-012, a New Fat Dissolving Molecule, Tested in Dercum's Disease Patients.</ArticleTitle>
        <Pagination>
          <StartPage>1165</StartPage>
          <EndPage>1166</EndPage>
          <MedlinePgn>1165-1166</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/DSS.0000000000002989</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gueta</LastName>
            <ForeName>Racheli</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Raziel Therapeutics Ltd, Rehovot, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Blaugrund</LastName>
            <ForeName>Eran</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Raziel Therapeutics Ltd, Rehovot, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bloomenfeld</LastName>
            <ForeName>Alon</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Raziel Therapeutics Ltd, Rehovot, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Herbst</LastName>
            <ForeName>Karen L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>Tucson, Arizona.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Dermatol Surg</MedlineTA>
        <NlmUniqueID>9504371</NlmUniqueID>
        <ISSNLinking>1076-0512</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002227">Carbazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015507">Drugs, Investigational</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000720429">RZL-012</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000274" MajorTopicYN="N">Adiposis Dolorosa</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002227" MajorTopicYN="N">Carbazoles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015507" MajorTopicYN="N">Drugs, Investigational</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050151" MajorTopicYN="N">Subcutaneous Fat</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33867475</ArticleId>
        <ArticleId IdType="doi">10.1097/DSS.0000000000002989</ArticleId>
        <ArticleId IdType="pii">00042728-900000000-97563</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>D'Andrea Molina J, Alborghetti Nai G, Pedro Cordeiro de Andrade TC, Milanez Morgado de Abreu MA. Dercum's disease: a rare and underdiagnosed disease. Ann Bras Dermatol 2019;94:251–3.</Citation>
        </Reference>
        <Reference>
          <Citation>Herbst KL, Asare-Bediako S. Adiposis Dolorosa is more than painful fat. Endocrinologist 2007;17:326–34.</Citation>
        </Reference>
        <Reference>
          <Citation>Caffery M, Beebe A. Pain: Clinical Manual for Nursing Practice. Baltimore, MD: V.V. Mosby Company; 1993.</Citation>
        </Reference>
        <Reference>
          <Citation>Wipf A, Lofgreen S, Miller DD, Farah RS. Novel use of deoxycholic acid for adiposis dolorosa (Dercum disease). Dermatol Surg 2019;45:1718–20.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
